Evidence map›Paper›PMID 39694544›Full record

ArticleThorax2025

Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment.

Gabriel Lavoie, Imran Howell, James Melhorn, Catherine Borg, Laura Bermejo-Sanchez, Jack Seymour, Maisha F Jabeen, Anastasia Fries, Gareth Hynes, Ian D Pavord and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thorax, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gabriel LavoieRespiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.ORCID 0009-0008-0280-0825
Imran HowellRespiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-6033-0488
James MelhornRespiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.ORCID 0000-0003-3977-7012
Catherine BorgRespiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Laura Bermejo-SanchezRespiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Jack SeymourRespiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Maisha F JabeenRespiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-1887-596X
Anastasia FriesRespiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Gareth HynesRespiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Ian D PavordRespiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-4288-5973
Nayia PetousiRespiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Timothy Sc HinksRespiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK timothy.hinks@ndm.ox.ac.uk.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Macrolides reduce exacerbations when added to inhaled therapy in severe asthma. However, there is little published evidence for effectiveness in patients treated with biologics. We conducted a retrospective audit of all patients who started azithromycin while on biologics in our centre. Compared with those that did not start azithromycin, these individuals had more exacerbations and a phenotype of chronic bronchitis and/or frequent purulent exacerbations. The addition of azithromycin to biologics was associated with reduced annual rates of steroid-treated and antibiotic-treated exacerbations and improved symptom scores (Asthma Control Questionnaire-5) but not with any improvement in lung function. Data support testing azithromycin in clinical trials in patients on biologics with residual exacerbations.

Indexed as

Anti-Bacterial AgentsAntibodies, MonoclonalAsthmaAzithromycinPulmonary EosinophiliaAdultAgedDrug Therapy, CombinationFemaleHumansMaleMiddle AgedRetrospective StudiesSeverity of Illness IndexTreatment OutcomeAnti-Bacterial AgentsAntibodies, MonoclonalAzithromycinAsthmaAsthma PharmacologyBacterial InfectionRespiratory Infection

Identifiers

PMID39694544
PMCPMC11877106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.